For patients with stage IV unresectable or metastatic melanoma, more options are available, including immunotherapy (ipilimumab plus nivolumab, nivolumab or pembrolizumab) or targeted therapy for BRAF-positive patients (dabrafenib plus trametinib, encorafenib plus binimetinib or vemurafenib plus cobimetinib) (19). The gene discussed is BRAF; the disease is metastatic melanoma.